Study identifier:D1690C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 156-Week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone.
Type 2 Diabetes
Phase 3
No
dapagliflozin, glipizide, metformin hydrochloride
All
1217
Interventional
18 Years - 150 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Mar 2015 by AstraZeneca
AstraZeneca
Bristol-Myers Squibb
This study is being carried out to see if dapagliflozin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glipizide (sulphonylurea) as an addition to metformin treatment.
Location
Location
La Plata, Argentina
Location
Córdoba, Argentina
Location
Capital Federal, Argentina
Location
Buenos Aires, Argentina
Location
Rosario, Argentina
Location
CABA, Argentina
Location
Santa Fe, Argentina
Location
Corrientes, Argentina
Arms | Assigned Interventions |
---|---|
Experimental: 1 dapagliflozin plus metformin | Drug: dapagliflozin Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks Drug: metformin hydrochloride Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks Other Name: Glucophage |
Active Comparator: 2 glipizide plus metformin | Drug: glipizide Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks Other Name: Glucotrol Drug: metformin hydrochloride Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks Other Name: Glucophage |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.